NCT00750269 · OUTCOME
Rate of Toxicity ≥ Grade 3 (Other Than DLT) Within One Year as Assessed by NCI CTCAE v4.0
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From start of SBRT until 1 year.
What was measured
Rate of patients developing any treatment-related toxicity during the first year following the start of SBRT that is not among the types considered as a dose-limiting toxicity.
Analysis population: All eligible patients who started study treatment
Groups in this outcome
Level 5: 10.0 Gy/FX
SBRT 50.0 Gy SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
Level 6: 10.5 Gy/FX
SBRT 52.5 Gy SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
Level 7: 11.0 Gy/FX
SBRT 55.0 Gy SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
Level 8: 11.5 Gy/FX
SBRT 57.5 Gy SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
Level 9: 12.0 Gy/FX
SBRT 60.0 Gy SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
| Group | Source count |
|---|---|
| Level 5: 10.0 Gy/FX | 8 |
| Level 6: 10.5 Gy/FX | 7 |
| Level 7: 11.0 Gy/FX | 14 |
| Level 8: 11.5 Gy/FX | 38 |
| Level 9: 12.0 Gy/FX | 33 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Level 5: 10.0 Gy/FX | 0 | Not reported | 0 | 0 | Not reported |
| Level 6: 10.5 Gy/FX | 0 | Not reported | 0 | 0 | Not reported |
| Level 7: 11.0 Gy/FX | 0 | Not reported | 0 | 0 | Not reported |
| Level 8: 11.5 Gy/FX | 12.1 | Not reported | 2.9 | 24.8 | Not reported |
| Level 9: 12.0 Gy/FX | 16.7 | Not reported | 3.4 | 28.2 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- group Id
- OG001
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- group Id
- OG002
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- group Id
- OG003
- lower Limit
- 2.9
- upper Limit
- 24.8
- value
- 12.1
- group Id
- OG004
- lower Limit
- 3.4
- upper Limit
- 28.2
- value
- 16.7
- denoms
- counts
- group Id
- OG000
- value
- 8
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 14
- group Id
- OG003
- value
- 38
- group Id
- OG004
- value
- 33
- units
- Participants
- description
- Rate of patients developing any treatment-related toxicity during the first year following the start of SBRT that is not among the types considered as a dose-limiting toxicity.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- SBRT 50.0 Gy SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
- id
- OG000
- title
- Level 5: 10.0 Gy/FX
- description
- SBRT 52.5 Gy SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
- id
- OG001
- title
- Level 6: 10.5 Gy/FX
- description
- SBRT 55.0 Gy SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
- id
- OG002
- title
- Level 7: 11.0 Gy/FX
- description
- SBRT 57.5 Gy SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
- id
- OG003
- title
- Level 8: 11.5 Gy/FX
- description
- SBRT 60.0 Gy SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
- id
- OG004
- title
- Level 9: 12.0 Gy/FX
- param Type
- NUMBER
- population Description
- All eligible patients who started study treatment
- reporting Status
- POSTED
- time Frame
- From start of SBRT until 1 year.
- title
- Rate of Toxicity ≥ Grade 3 (Other Than DLT) Within One Year as Assessed by NCI CTCAE v4.0
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle